4basebio UK Societas (GB:4BB) has released an update.
4basebio UK Societas has reported a successful financial year in 2023, achieving significant milestones including the first sale of its High Quality synthetic DNA and receiving its first order for GMP grade product. The company, which specializes in the manufacture of synthetic DNA for the cell and gene therapy and vaccine markets, also advanced its technology platforms, evidenced by client HelixNano Technologies Inc.’s approval for mRNA vaccine trials. With a focus on expanding commercial activity and product innovation, 4basebio anticipates strong growth in 2024.
For further insights into GB:4BB stock, check out TipRanks’ Stock Analysis page.
